Qiagen N.V (0RLT) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Qiagen N.V €39.28, price €40.41, upside -2.8%, quality 74 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range €27.48 – €49.82 · fair‑value band €27.50 – €51.08 · the €40.41 price screens above the €39.28 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
Show more
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Stock analysis
Qiagen N.V (0RLT) currently trades at €40.41, while our model-based Fair Value estimate is €39.28, so the stock looks roughly fairly valued today (gap 2.9%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €32.59 per share, and 2 of the 23 models we run sit above the €40.41 price.
Bear case: the Asset-Based group reads lowest at €6.59, and 21 of the 23 models stay below the price. Evidence for this calculation is medium.
Scenario range: €27.50 (bear) to €51.08 (bull), the price of €40.41 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Qiagen N.V reported revenue of €1.9B in FY2020 versus €1.3B in FY2016, a compound +8.7%/yr. Reported net income was €359M in FY2020, compounding +45.4%/yr from FY2016.
Key figures
Market cap €11.5B · P/S ratio 5.47 · Net margin 19.2% · Return on equity 11.9% · Return on assets (EBIT) 3.2% · Operating margin 23.8% · Revenue (TTM) €2.1B · Revenue growth (YoY) +1.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 47% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −3%, 0RLT screens cheaper than that median.
Fair Value models
Bear €27.50Fair Value €39.28Bull €51.08
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.77/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+22.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.7%
’16
’17
’18
’19
’20
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
6.6% (2016) → 20.7% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Qiagen N.V Fair Value". https://www.fairvalue-calculator.com/stock/0RLT
Frequently asked questions
Is Qiagen N.V (0RLT) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €39.28 versus a price of €40.41, about −3% upside (fairly valued).
What is the fair value of 0RLT?
Our model-based fair value for Qiagen N.V is €39.28 (as of Sep 23, 2026), built from audited fundamentals. The current price: €40.41.
What is the quality score of 0RLT?
Qiagen N.V has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Qiagen N.V (0RLT)?
Our model-based price target is the fair value of €39.28 (as of Sep 23, 2026) from 23 valuation models. Cautious scenario €27.50, optimistic scenario €51.08. It is a calculation from audited fundamentals, not an analyst target.
What is the Qiagen N.V stock forecast for 2026?
Our models put fair value at €39.28, about −3% upside versus a price of €40.41 (fairly valued). Cautious scenario €27.50, optimistic scenario €51.08. The calculation is refreshed regularly with new filings.
What is the revenue of Qiagen N.V (0RLT)?
Qiagen N.V reported trailing-twelve-month revenue of about €2.1B (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Qiagen N.V (0RLT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Qiagen N.V it is €39.28 per share (as of Sep 23, 2026), against a price of €40.41. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Qiagen N.V stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 0RLT trades above its calculated fair value: price €40.41, fair value €39.28, a gap of about −3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0RLT?
No. The price is what the market pays today (€40.41); the fair value is what the company's own numbers justify (€39.28). For Qiagen N.V the two are €1.13 per share apart. That gap is exactly why we show both numbers side by side.
How much is Qiagen N.V worth?
The market values Qiagen N.V at about €11.5B (market capitalisation, as of Sep 23, 2026). Per share that is €40.41; our models calculate a fair value of €39.28 per share.
What do the bullish and bearish scenarios say about 0RLT?
Our models span a range for Qiagen N.V: cautious scenario €27.50, base €39.28, optimistic €51.08 per share (as of Sep 23, 2026, price €40.41). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0RLT from its 52-week high?
Qiagen N.V trades at €40.41, about 13% below its 52-week high of €46.51 and 47% above the low of €27.48 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €39.28 is for.
Which stocks are comparable to Qiagen N.V?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Qiagen N.V stock attractive at the current price?
The data as of Sep 23, 2026: price €40.41, calculated fair value €39.28 (−3%), Quality Score 74/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0RLT calculated?
We run Qiagen N.V through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €39.28, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Qiagen N.V itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Qiagen N.V (0RLT)?
The closing price on Oct 2, 2026 was €40.41. Our model-based fair value is €39.28, about −3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Qiagen N.V right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (€27.50 to €51.08) leaves room in how you read the outcome.
Key figures of Qiagen N.V
How large is the market capitalisation of Qiagen N.V (0RLT)?
The market capitalisation of Qiagen N.V is €11.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Qiagen N.V (0RLT)?
The price-to-sales ratio of Qiagen N.V is 5.47 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Qiagen N.V (0RLT)?
The net margin of Qiagen N.V is 19.2% (fiscal year 2020). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Qiagen N.V (0RLT)?
The return on equity (ROE) of Qiagen N.V is 11.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Qiagen N.V (0RLT)?
On an EBIT basis the return on assets of Qiagen N.V is 3.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Qiagen N.V (0RLT)?
The operating margin of Qiagen N.V is 23.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Qiagen N.V (0RLT)?
Revenue at Qiagen N.V is growing +1.8% versus a year earlier (3y avg +9.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Qiagen N.V (0RLT)?
Earnings per share at Qiagen N.V are growing −23.8% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
